January 11, 2023
Life Sciences
  • The Food and Drug Administration (FDA) said its advisory panel will meet on February 15 to review Emergent Biosolutions Inc’s over-the-counter nasal spray to treat suspected opioid overdoses. Emergent is asking the FDA to approve for the prescription-free sale of Narcan, its nasal spray form of the drug naloxone. Narcan is already cleared for the treatment of opioid overdose in the country. (Article here)